Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 23

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 23
---
 to pay in cash to DiamiR, a fee in the amount equal to the higher of (i) 70% of cash that Aptorum has as of the date of
Termination, and (ii) $2,000,000 (the “Termination Fee”). In the event that the Merger Agreement is terminated and that Aptorum
has not raised capital by issuance of its equity securities during the Interim Period, each party agrees to bear its own expenses incurred
with the Merger and the related transactions.

Reasons for the Merger

Since inception, the Company has sought to maximize
shareholder value by licensing and acquiring technologies that have scientific merit and ultimately, meaningful market value after commercialization.
We believe great opportunity exists for therapeutic agents developed for CNS indications, including neurodegenerative diseases such as
Alzheimer’s and Parkinson’s, as well as certain cancers like glioblastoma and neuroblastoma. Due to the heterogeneity of these
diseases, there is a wide spectrum of clinical manifestations and outcomes in patients with these conditions. Therefore, there is a strong
need for accurate, minimally invasive biomarkers reflective of pathophysiological processes underlying these diseases that can be used
for disease progression and treatment response monitoring. As such, the Company’s management finds great value in DiamiR’s
innovation and proprietary technology.

DiamiR’s platform technology,
which is based on targeted selection and quantitative analysis of organ-enriched, including brain-enriched, microRNA (miRNAs) detectable
in blood plasma, has a strong potential to provide molecular diagnostic solutions for risk assessment and monitoring of neuro and other
indications in clinical trials, which we believe will enable more effective drug development for these indications. DiamiR’s CLIA/CAP-certified
lab offers and is planning to offer additional genetic and protein markers used in clinical trials for. For example, DiamiR’s validated
APOE genotyping test (APOE e4 allele is an established risk factor of AD, while APOE e2 is considered to be neuroprotective)
can be used as a screening tool for enrollment into clinical trials targeting APOE e4 carriers or non-carriers. The Company is
aware of a need in such test first-hand as it holds a position in a private life sciences company Alzheon that is developing a therapeutic
agent for AD patients who are APOE e4 carriers. The Company’s private investment position in Alzheon,